Skin Infections, Bacterial Clinical Trial
Official title:
An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative, Phase III Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00555061 -
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
|
Phase 4 | |
| Completed |
NCT01445600 -
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
|
N/A | |
| Completed |
NCT00684177 -
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
|
Phase 3 | |
| Completed |
NCT01153880 -
United States Pharmacovigilence Retapamulin-Prescribing
|
N/A | |
| Completed |
NCT01209078 -
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
|
Phase 2 | |
| Completed |
NCT00852540 -
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
|
Phase 3 | |
| Completed |
NCT01812382 -
Retapamulin Microdialysis Feasibility Study
|
Phase 1 |